Report overview
Chemotherapy-induced nausea and vomiting (CINV) is a common side-effect of many cancer treatments. Nausea and vomiting are two of the most feared cancer treatment-related side effects for cancer patients and their families. In 1983, Coates et al. found that patients receiving chemotherapy ranked nausea and vomiting as the first and second most severe side effects, respectively. Up to 20% of patients receiving highly emetogenic agents in this era postponed, or even refused, potentially curative treatments. Since the 1990s, several novel classes of antiemetics have been developed and commercialized, becoming a nearly universal standard in chemotherapy regimens, and helping to better manage these symptoms in a large portion of patients. Efficient mediation of these unpleasant and sometimes crippling symptoms results in increased quality of life for the patient, and better overall health of the patient, and, due to better patient tolerance, more effective treatment cycles.
Affecting 70-80% of patients undergoing chemotherapy, chemotherapy-induced nausea and vomiting (CINV) is one of chemotherapy's most debilitating side effects, often attributed as a leading cause of premature discontinuation of cancer treatment.
This report aims to provide a comprehensive presentation of the global market for Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs. This report contains market size and forecasts of Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs in global, including the following market information:
Global Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Market Sales, 2018-2023, 2024-2029, (M Units)
Global top five Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs companies in 2022 (%)
The global Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs market was valued at US$ 2431.4 million in 2022 and is projected to reach US$ 2182.5 million by 2029, at a CAGR of -1.5% during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
Global Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs key players include Haisco, Merck, Mundipharma, Qilu Pharma, Heron Therapeutics, Teva, etc. Global top six manufacturers hold a share about 30%.
North America is the largest market, with a share about 35%, followed by Europe and Asia-Pacific, both have a share about 60 percent.
In terms of product, 5-HT3 Inhibitors is the largest segment, with a share over 70%. And in terms of application, the largest application is Acute CINV, followed by Delayed CINV and Breakthrough CINV.
We surveyed the Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Market, by Type, 2018-2023, 2024-2029 ($ Millions) & (M Units)
Global Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Market Segment Percentages, by Type, 2022 (%)
5-HT3 Inhibitors
NK1 Inhibitors
Others
Global Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Market, by Application, 2018-2023, 2024-2029 ($ Millions) & (M Units)
Global Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Market Segment Percentages, by Application, 2022 (%)
Acute CINV
Delayed CINV
Breakthrough CINV
Others
Global Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions) & (M Units)
Global Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs revenues in global market, 2018-2023 (Estimated), ($ millions)
Key companies Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs revenues share in global market, 2022 (%)
Key companies Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs sales in global market, 2018-2023 (Estimated), (M Units)
Key companies Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs sales share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Heron Therapeutics
Merck
Eisai
Mundipharma
Qilu Pharma
Teva
Novartis
Roche
Mylan
Baxter
GSK
Helsinn
Southwest Pharma
Haisco
Sun Pharma
Outline of Major Chapters:
Chapter 1: Introduces the definition of Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs, market overview.
Chapter 2: Global Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs market size in revenue and volume.
Chapter 3: Detailed analysis of Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Global Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs capacity by region & country.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 11: The main points and conclusions of the report.
